Patent Cliff – Talk Bio

A closer look at pharmas top patent losses in 2025

1 month ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff

2 months ago talkbio0Tagged Impact food supplement, IRA, Keytruda, Merck, Patent Cliff, Prices, Sales - occupational activity, U.S.

Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda

Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff

10 months ago talkbio0Tagged Acquisitions, Biological Factors, Biosimilars, Drug Industry, Johnson & Johnson, mergers, Myers, Patent Cliff, patent expirations, Pfizer, Revenue Loss, squibb

Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions